{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:10:25Z","timestamp":1746418225736,"version":"3.28.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,23]]},"DOI":"10.7759\/cureus.72177","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T08:32:33Z","timestamp":1729672353000},"source":"Crossref","is-referenced-by-count":2,"title":["Isatuximab for Stem Cell Transplant-Ineligible Multiple Myeloma: An Editorial"],"prefix":"10.7759","author":[{"given":"Abdul Haseeb","family":"Hasan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Ali","family":"Abid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bisma","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1240318","article-title":"Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed\/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials","volume":"13","author":"Ye L","year":"2023","unstructured":"Ye L, Zhou F, Cheng D, et al.. Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed\/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials. Front Oncol. 2023, 13:1240318. 10.3389\/fonc.2023.1240318","journal-title":"Front Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01936-7","article-title":"Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible\/with no immediate intent for autologous stem cell transplantation","volume":"37","author":"Ocio EM","year":"2023","unstructured":"Ocio EM, Perrot A, Bories P, et al.. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible\/with no immediate intent for autologous stem cell transplantation. Leukemia. 2023, 37:1521-9. 10.1038\/s41375-023-01936-7","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01771","article-title":"Isatuximab acts through FC-dependent, independent, and direct pathways to kill multiple myeloma cells","volume":"11","author":"Zhu C","year":"2020","unstructured":"Zhu C, Song Z, Wang A, et al.. Isatuximab acts through FC-dependent, independent, and direct pathways to kill multiple myeloma cells. Front Immunol. 2020, 11:1771. 10.3389\/fimmu.2020.01771","journal-title":"Front Immunol"},{"key":"ref4","unstructured":"FDA Approves Isatuximab-Irfc With Bortezomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. (2024). Accessed. October 06, 2024: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-isatuximab-irfc-bortezomib-lenalidomide-a...."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","author":"Facon T","year":"2024","unstructured":"Facon T, Dimopoulos MA, Leleu XP, et al.. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024, 10.1056\/NEJMoa2400712","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/311108-isatuximab-for-stem-cell-transplant-ineligible-multiple-myeloma-an-editorial","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T08:32:35Z","timestamp":1729672355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/311108-isatuximab-for-stem-cell-transplant-ineligible-multiple-myeloma-an-editorial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":5,"URL":"https:\/\/doi.org\/10.7759\/cureus.72177","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,23]]}}}